A drug selected for the latest round of Medicare drug price negotiations stands to get dropped because a lower-cost ...
The use of biosimilars saved Blue Cross members and employee groups $67 million in 2024 and $80 million in 2025, according to a news release. The savings come amid a cost-cutting push at Blue Cross to ...
Add Yahoo as a preferred source to see more of our stories on Google. FDA Commissioner Marty Makary speaks in the Oval Office at the White House on May 05, 2025. (Anna Moneymaker via Getty Images) ...
The Food and Drug Administration said it will take steps to speed up the process of developing generic versions of complex biological drugs, in a bid to increase cheaper competition for expensive ...
The Association for Accessible Medicines’ annual U.S. Generic & Biosimilar Medicines Savings Report, in partnership with the IQVIA Institute, reveals that the use of Food and Drug Administration ...
The FDA has decided that biosimilar medications must have unique naming features, distinguishing them from brand-name biologics in a move to improve patient safety, according to a STAT news report. 1.
Biosimilars are near-identical versions of biologic cancer drugs, available at lower costs. Germany saves hundreds of millions annually from just one biosimilar drug. Patient mistrust and policy ...
Patients with diabetic macular edema can expect similar BCVA improvements and CST reductions using an aflibercept biosimilar compared with conventional aflibercept. An aflibercept biosimilar is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results